Table 1.
Effects of cannabinoids modulation and Cannabis-derived compounds in audiogenic seizures.
| References | Subjects | Treatment/manipulation | Results |
|---|---|---|---|
| Carlini et al. (1973) | Male mice Male rats |
CBD (10, 50, and 200 mg/kg; i.p.), CBD (25 mg/kg; i.p.) |
Reduced wild running and tonic-clonic seizures |
| Boggan et al. (1973) | C57BL/6 mice submitted to AS priming | THC (2.5, 5, and 10 mg/kg; i.p.) | Reduced wild running, tonic, and clonic seizure |
| Consroe and Wolkin (1977) | Adult male rats | CBD (17 mg/kg; orally) | Reduced tonic-clonic seizures |
| Consroe et al. (1981) | Adult male rats | CBD (82.4 mg/kg; i.p.), CBD (14.9 mg/kg; i.v.) |
Reduced AS frequency |
| Samineni et al. (2011) | Male and Female GEPR-9s | AM 251 (50, 100, and 200 pmol; intra-ventrolateral PAG; bilateral) | Decreased post-ictal analgesia (AS was not assessed) |
| Vinogradova et al. (2011) | Wistar rats susceptible to AS | SR 141716 (30 mg/kg; i.p.) | Facilitated AS in resistant animals; increased AS duration; facilitated limbic seizure expression |
| Busquets-Garcia et al. (2013) | Fmr1–/y mice: Fragile X Syndrome model | SR 141716 (1 mg/kg; i.p.) AM 630 (1 mg/kg; i.p.) | Attenuated AS and anxiety-like behavior |
| Hill et al. (2012) | DBA/2 mice | CBDV (50, 100, and 200 mg/kg; i.p.) | Reduced tonic seizures; Reduced mortality; increased the number of seizure-free animals |
| Hill et al. (2013) | DBA/2 mice | Cannabis-derived compounds rich in CBD + CBDV (Several doses) | Reduced wild running, tonic, and clonic seizures |
| Vinogradova and Van Rijn (2015) | Adult male KMs | WIN 55,212-2 (4 mg/kg; s.c.) | Increased the latency to post-tonic clonus behaviors |
| Citraro et al. (2016) | DBA/2 mice | Cannabinoid agonists: N-palmitoylethanolamine (5–40 mg/kg; i.p.), Arachidonyl-2-chloroethylamide (0.5–30 mg/kg; i.p.), WIN 55,212-2 (2.5–60 mg/kg; i.p.) |
All drugs attenuated AS. Anticonvulsant effects were antagonized by NIDA-41020 (0.5–2 mg/kg; i.p.), a CB1R antagonist. |
| Gu et al. (2019) | Angelman Syndrome mice susceptible to AS | CBD (10, 20, 50, and 100 mg/kg; i.p.) | Attenuated wild running and tonic-clonic seizures. More than 80% of mice were seizure-free with CBD 100 mg/kg |
| Santos et al. (2020) | Male GEPR-3s | WIN 55,212-2 (1, 1.5, 2 mg/kg; i.p.), CP 55940 (26.5 nmol; intra-DLSC, bilateral) |
Systemic and intra-DLSC CB1R activation attenuated AS severity; Systemic effect was not modified by intra-DLSC CB1R antagonist |
| Lazarini-Lopes et al. (2020a) | Male WARs | Characterization of CB1R expression after acute and chronic AS | Increased CB1R in the hippocampus of WAR (WAR × Wistar); Acute and chronic AS increased CB1R in amygdala and hippocampus of WARs |